No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CCCC240816C8000
- 0.35
- -0.15-30.00%
15min DelayClose Jul 22 15:25 ET
0.35High0.35Low
0.35Open0.50Pre Close15 Volume2.05K Open Interest8.00Strike Price525.00Turnover124.53%IV35.55%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.2642Delta0.1633Gamma22.40Leverage Ratio-0.0134Theta0.0009Rho5.92Eff Leverage0.0053Vega
Intraday
- 5D
- Daily
News
Small-Cap Stocks Are Having a Moment. Check Out the 10 Biggest Winners.
Chatter about the timing of the Federal Reserve's first interest-rate cuts has shifted all the market hype from Goliath to David.
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
Express News | C4 Therapeutics To Present Preliminary Monotherapy Data From Ongoing Phase 1 Trial Of CFT1946 At ESMO Congress 2024
C4 Therapeutics to Present Preliminary Monotherapy Data From the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation
C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why
C4 Therapeutics, Inc. (CCCC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy).
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science
Comments
$C4 Therapeutics(CCCC.US$
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The present...
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The present...
$C4 Therapeutics(CCCC.US$
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
$C4 Therapeutics(CCCC.US$ doesnt look like its gonna go up by much ..
$C4 Therapeutics(CCCC.US$ C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment
1
The consensus is bullish on C4 Therapeutics, with increased forecasts and a higher price target. However, potential flags include dilutive stock issuance over the past year.
2
Read more